Ivermectin in the treatment of COVID-19-friend or foe?

被引：0
|
作者：
Schellack, N. [1 ]
Padayachee, N. [2 ]
Schellack, G. [3 ]
机构：
[1] Univ Pretoria, Pretoria, South Africa
[2] Univ Witwatersrand, Clin Pharm, Dept Pharm & Pharmacol, Johannesburg, South Africa
[3] Clin Res & Appl Pharmacol, Cape Town, South Africa
来源：
SA PHARMACEUTICAL JOURNAL | 2021年 / 88卷 / 01期
关键词：
COVID-19; SARS-CoV-2; ivermectin; avermectin; macrocyclic lactone; endectocide; ADVERSE-REACTIONS; SAFETY; PHARMACOKINETICS; PROTEIN; DENGUE; DRUG;
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
The global number of deaths due to COVID-19 is almost at the two million mark, with over 35 000 deaths in South Africa. Although there are hopes of a safe and effective vaccination programme, the increasing number of COVID-19 cases in the country is putting a significant strain on the healthcare system. Ivermectin, an antiparasitic drug, has been widely published on social media platforms and news outlets as a so-called miracle drug for the treatment of COVID-19. Ivermectin is not registered in SA as a drug for human use, but rather as a veterinary and agricultural product. Currently, from a small number of randomised controlled trials (RCTs), there does seem to be a signal of evidence for the use of ivermectin in the management of COVID-19. Pharmacists must, however, remain cognisant of their ethical responsibilities as well as the applicable regulations that prohibit the procurement and dispensing of any unregistered medicine.
引用
收藏
页码：11 / +
页数：5
相关论文
共 50 条
  • [41] Friend or Foe - The Potential Mechanisms of Nicotine's Protective Role in COVID-19
    Lin, Mosi
    Zefi, Sidorela
    Zhao, Warren
    Ashby, Charles
    Mantell, Lin
    [J]. FREE RADICAL BIOLOGY AND MEDICINE, 2023, 208 : S89 - S89
  • [42] From Foe to Friend in COVID-19: Renin-Angiotensin System Inhibitors
    Kidde, Jason
    Sahebkar, Amirhossein
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2021, 223 (01): : 174 - 175
  • [43] Gastrointestinal symptoms in patients with coronavirus disease 2019 (COVID-19) - friend or foe?
    Lewandowski, Konrad
    Kaniewska, Magdalena
    Rosolowski, Mariusz
    Tworek, Adam
    Rydzewska, Grazyna
    [J]. GASTROENTEROLOGY REVIEW-PRZEGLAD GASTROENTEROLOGICZNY, 2022, 17 (03): : 219 - 226
  • [44] Granulocyte-macrophage colony stimulating factor in COVID-19: friend or foe?
    Mehta, Puja
    Chambers, Rachel C.
    Dagna, Lorenzo
    [J]. LANCET RHEUMATOLOGY, 2021, 3 (06): : E394 - E395
  • [45] Endothelin receptor antagonists for pulmonary arterial hypertension and COVID-19: Friend or foe?
    Badagliacca, Roberto
    Sciomer, Susanna
    Petrosillo, Nicola
    [J]. JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2020, 39 (07): : 729 - 730
  • [46] SGLT2 inhibition during the COVID-19 epidemic: Friend or foe?
    Scheen, A. J.
    [J]. DIABETES & METABOLISM, 2020, 46 (05) : 343 - 344
  • [47] Nationwide practice on awake prone positioning for COVID-19 patients: 'a friend or foe?'
    Wilkinson, D.
    West, R.
    [J]. ANAESTHESIA, 2021, 76 : 92 - 92
  • [48] Bradykinin in the Treatment of Hypertension: Friend or Foe?
    Marketou, Maria E.
    Vardas, Panos E.
    [J]. HELLENIC JOURNAL OF CARDIOLOGY, 2012, 53 (02) : 91 - 94
  • [49] FDA: IVERMECTIN NOT APPROVED FOR COVID-19 TREATMENT
    不详
    [J]. JAVMA-JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION, 2020, 256 (11): : 1189 - 1189
  • [50] Paracetamol in the home treatment of early COVID-19 symptoms: A possible foe rather than a friend for elderly patients?
    Pandolfi, Sergio
    Simonetti, Vincenzo
    Ricevuti, Giovanni
    Chirumbolo, Salvatore
    [J]. JOURNAL OF MEDICAL VIROLOGY, 2021, 93 (10) : 5704 - 5706
12345